Latest Options News

Tourism Holdings Limited (THL) has received a revised acquisition proposal from a BGH-led consortium offering NZ$3.10 per share. Meanwhile, THL has downgraded its FY26 profit guidance and raised its net debt forecast amid ongoing global travel uncertainties.

Racura Oncology has locked in an underwriting agreement covering nearly 1.84 million expiring options, ensuring up to $2.3 million in fresh capital to back its cancer drug development programs.

Hawk Resources has dispatched materials for a $1.97 million non-renounceable entitlement offer priced at 3 cents per share, offering shareholders free options and a chance to apply for shortfall shares.

Betashares Capital Ltd has released estimated monthly distribution amounts for May 2026 for 20 ETFs trading on the ASX AQUA market, with payments scheduled for mid-June. These figures are preliminary and subject to adjustment in the final announcement.

Novo Resources Corp has closed Tranche 2 of its placement, raising approximately C$1.93 million and issuing options to joint lead managers and participants, while Northern Star retains a near 10% stake.

Ventia Services Group has landed a NZD 125 million contract to maintain and renew roads for New Zealand's Far North District Council, marking a significant expansion of its infrastructure services footprint.

ReadCloud Limited’s 1H26 results reveal robust growth in school-focused businesses, with cash receipts up 22% and operating cash flow rising 10%, positioning the company to outperform its FY26 earnings guidance.

Pure Resources (ASX: PR1) has closed a $3 million placement, issuing 12 million shares after shareholder approval, while also issuing options and advisory shares to support exploration and cutting-edge carbon nanotube fibre research.

Atomic Eagle has sharpened its uranium exploration focus at Muntanga North, Zambia, completing 53 of 80 planned line kilometres of ground radiometric surveys that confirm and refine large-scale anomalies. Drilling is set to begin imminently on these high-priority targets.

VRX Silica has kicked off a $6.23 million renounceable entitlement offer, underwritten to $2 million, to fund key development activities at its Arrowsmith North silica sand project including a strategic property purchase and engineering works.

Terragen Holdings secures a landmark supply agreement for its probiotic and biostimulant products with Ravensworth Feedlot, alongside a $2.8 million funded trial at Mort & Co’s Grassdale feedlot to validate its probiotic’s impact on cattle performance.

Nexalis Therapeutics has locked in a $53 million non-dilutive funding facility with Point8 Capital, replacing its previous lender and supporting three clinical programs targeting breakthrough cancer pain, panic disorder, and treatment-resistant depression.